Veru (VERU)
(Delayed Data from NSDQ)
$1.47 USD
+0.14 (10.53%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.47 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Veru Inc. [VERU]
Reports for Purchase
Showing records 1 - 20 ( 92 total )
Company: Veru Inc.
Industry: Medical - Products
F1Q24 Financial Highlights Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2b Enobosarm and GLP-1 Drug Combo Trial Cleared to Proceed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
IND Application Submitted for Enobosarm to Prevent Muscle Loss Associated With GLP-1 Drugs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Enobosarm Combo Therapy May Prevent Muscle Wasting in Weight Loss; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Expanded Sabizabulin Phase 3 Trial to Start in 4Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Company: Veru Inc.
Industry: Medical - Products
F2Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Confirmatory Phase 3 COVID-19 Trial to Start in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
ENTADFI Sold For Total Consideration of Up to $100M; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
In Vitro Data Show Inhibition of Poxviruses by Sabizabulin; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Positive Preclinical Data in Influenza-Induced ARDS; Pipeline Restructured; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
FDA Declines to Grant EUA to Sabizabulin; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
F1Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
FY2022 Financial Results Reported; Reiterate Buy; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
FDA AdComm Says No to COVID-19 EUA Application; Reiterate Buy; Lowering PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Additional COVID-19 Clinical Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Company: Veru Inc.
Industry: Medical - Products
FDA AdCom to Discuss Sabizabulin COVID-19 EUA Application; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Sabizabulin Granted Expedited Regulatory Pathway in Australia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y